Skip to main content
. 2017 Aug 7;7:7405. doi: 10.1038/s41598-017-07565-2

Figure 2.

Figure 2

Validation of GR inhibitor hits. A549/NF-κB-luc reporter cells were treated with 5 ng/mL IL-1β ± 10 nM Dex and a pan-kinase inhibitor or kinase GSK3β inhibitors (A) or other compounds (B) as indicated. Luciferase assays were performed after 18 h treatment. The luciferase activity in control cells with 5 ng/mL IL-1β treatment was normalized to 1. The luciferase activity of cells treated with IL-1β + Dex and hits was calculated and compared to that of cells treated with IL-1β + Dex. *P < 0.05. **P < 0.01, ***P < 0.005.